BioSpace News Archive

Biotech Bay

XOMA Announces Commencement of Rights Offering

XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced the previously announced rights offering to raise gross proceeds of approximately $22 million (the “Rights Offering”)

December 2, 2019
·
4 min read
Business

AGTC Announces Departure of Chief Medical Officer, Company on Track to Announce XLRP and ACHM Data in January 2020

Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, announced that Theresa Heah, M.D., Chief Medical Officer, has resigned from the company to pursue other opportunities.

December 2, 2019
·
5 min read
Policy

New Early Breast Cancer Drug Approved by Singapore Health Sciences Authority

NERLYNX® (neratinib) now approved in Singapore for HER2+ breast cancer patients following adjuvant trastuzumab-based therapy

December 2, 2019
·
6 min read
Deals

Perrigo Announces Closing of Prevacid®24HR (OTC) Acquisition, Advancing Consumer Self-Care Growth Strategy

Perrigo Company plc announced that it has completed the acquisition of the branded over-the-counter rights to Prevacid®24HR.

December 2, 2019
·
4 min read
Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference

Eli Lilly and Company will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019.

December 2, 2019
·
1 min read
Policy

Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer

Puma Biotechnology, Inc., a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia has received marketing approval of NERLYNX® in Singapore from the Health Sciences Authority, a statutory board under the Ministry of Health of the Singapore Government.

December 2, 2019
·
6 min read
Drug Development

1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Cellectis announced that the first patient enrolled in the dose escalation Phase 1 clinical study for its UCART22 product candidate has been dosed at The University of Texas MD Anderson Cancer Center.

December 2, 2019
·
5 min read
Business

Elanco Animal Health Appoints Chief Sustainability Officer, Emphasizes Continued Commitment to Advance Well-Being of Animals, People and Planet

Elanco Animal Health Inc. announced Sara Place, Ph.D., has joined the company as Chief Sustainability Officer, emphasizing the company’s continued commitment to make an impact on societal challenges by improving the health of animals.

December 2, 2019
·
3 min read
Deals

Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - December 2, 2019

Dicerna™ Pharmaceuticals, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 178,500 shares of common stock to be distributed among eight new employees, with a grant date of December 2, 2019.

December 2, 2019
·
3 min read
Pharm Country

Piper Jaffray to Host 31st Annual Healthcare Conference

Piper Jaffray Companies, a leading investment bank and institutional securities firm, will host its 31st annual Healthcare Conference in New York on December 3-5, 2019.

December 2, 2019
·
3 min read